BridgeBio Pharma will present interim analysis data from its Phase 3 FORTIFY trial of BBP-418 for limb-girdle muscular dystrophy at the 2026 MDA conference. The study has met efficacy endpoints, with additional presentations planned from academic collaborators. The company previously announced its Q4 and full year 2025 financial results release date.
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration BTK inhibitor regimen for CLL/SLL and cleared monthly dosing for amivantamab in EGFR-mutated NSCLC. Additional regulatory reviews are underway for PCNSL and breast cancer treatments.
OncoHost announced publication of a study in JPBA introducing a computational framework that harmonizes serum and plasma proteomic datasets, enabling researchers to combine previously incompatible specimen types for biomarker research.
